Investigational Extended Wear Insulin Infusion Set in People With Type 1 Diabetes

Completed · Not applicable

Conditions studied: Type1diabetes

In brief

The purpose of this study is to collect clinical data to support a 7-day wear of the Extended Wear Infusion Set (EWIS). Participants will be asked to: 1. Wear the EWIS for up to 7 consecutive days for 12 consecutive wear periods 2. Perform blood glucose and ketone measurements if continuous glucose meter is ≥250mg/dL for one hour

Key facts

Study ID

NCT06273124

Run by

Tandem Diabetes Care, Inc.

People needed

260

Starts

2024-03-07

Expected to finish

2024-12-11

Last updated by the study team

2025-09-24

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Inclusion Criteria:
• Age 18 to 80 years old inclusive
• Generally in good health, as determined by the investigator
• Living in the United States with no plans to move outside the United States during the study
• Diagnosis of T1D for at least 12 months
• Minimum of 6 months of insulin pump experience and at least 3 months of current experience with a Tandem pump
• Using Tandem t:slim X2 insulin pump with Control-IQ technology for a minimum of 1 month at the time of enrollment
• Minimum of 14 days of Control-IQ data immediately preceding screening that demonstrate pump use compliance, including at least 85% of time with Control-IQ technology active
• HbA1c <9.0% in the last 6 months.
• Willing to implement and adhere to pump alert/alarm settings on a study-provided pump as instructed during the study
• Willing to wear each investigational infusion set for up to 7 days during each of the 12 consecutive wear periods in the study
• Willing to perform blood ketone and blood glucose (fingerstick) measurements as directed using provided ketone and blood glucose meters and strips
• Access to internet for required periodic uploads of study device data
• BMI in the range 18-35 kg/m2, both inclusive
• Currently using one of the following insulins with no expectation of a need to change insulin type during the study:
• Humalog™* (insulin lispro)
• NovoLog™* (insulin aspart)
• Using Humalog™ insulin lispro or NovoLog™ insulin aspart for a minimum of 1 month at the time of enrollment
• Willing to change insulin cartridge every 48-72 hours, as recommended by patient's healthcare provider during the study
• Has routine access to a smart phone e.g., ability to receive text messages
• Has the ability to understand and comply with protocol procedures and to provide informed consent (i.e., English proficient in both verbal and written communication)

You may not qualify if…

• Concurrent use of any non-insulin glucose-lowering agent, other than metformin (for example, GLP-1 agonists, Symlin, DPP-4 inhibitors, SGLT-2 inhibitors, sulfonylureas)
• Female subject is pregnant, planning to become pregnant, or not using adequate method of contraception
• Episodes of severe hypoglycemia in the last 6 months resulting in:
• Medical Assistance (i.e., paramedics, hospital evaluation or hospitalization)
• Loss of consciousness
• Seizures
• One or more episodes of diabetic ketoacidosis (DKA) in the last 6 months requiring hospitalization
• Currently on a ketogenic or low-carbohydrate diet of less than 60 grams of carbohydrates per day, or intending to begin one during the study period
• Known cardiovascular disease considered to be clinically relevant by the investigator
• Known history of any of the following conditions:
• Cushing's Disease
• Pancreatic islet cell tumor
• Insulinoma
• Lipodystrophy
• Extensive lipohypertrophy, as assessed by the investigator
• Currently undergoing treatment with:
• Systemic oral or intravenous corticosteroids (current or within the last 8 weeks from screening),
• Thyroid hormones, unless use has been stable during the past 3 months
• Significant history of any of the following, that in the opinion of the investigator would compromise safety or successful study participation:
• Alcoholism
• Drug abuse
• Significant acute or chronic illness, that in the opinion of the investigator might interfere with safety or integrity of study results
• Current participation in another clinical drug or device study
• Immediate family member (spouse, biological or legal guardian, child, sibling, parent) who is a study site personnel directly affiliated with this study or who is an employee of Capillary Biomedical

Where it is running

• Hoag Memorial Hospital Presbyterian — Newport Beach, California, United States
• Stanford University — Stanford, California, United States
• Barbara Davis Center — Aurora, Colorado, United States
• Endocrine Research Solutions — Roswell, Georgia, United States
• Rocky Mountain Clinical Research — Idaho Falls, Idaho, United States
• Northwestern University — Evanston, Illinois, United States
• Massachusetts General Hospital — Boston, Massachusetts, United States
• Henry Ford Health System — Detroit, Michigan, United States
• International Diabetes Center - HealthPartners Institute — Minneapolis, Minnesota, United States
• Mayo Clinic — Rochester, Minnesota, United States
• Icahn School of Medicine at Mt. Sinai — New York, New York, United States
• SUNY Upstate Medical University — Syracuse, New York, United States
• Texas Diabetes and Endocrinology — Austin, Texas, United States
• Rainier Clinical Research Center — Renton, Washington, United States
• University of Washington — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.